Roivant Sciences (ROIV) EBT Margin Growth (1y) (2021 - 2026)
Powered by 
Analysis
Roivant Sciences (ROIV) EBT Margin Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.37 Bn | 197.38 Bn | 7.24 Bn | 1,045.00 |
| 2 | Gilead Sciences | 181.12 Bn | 177.94 Bn | 6.22 Bn | -16,571.00 |
| 3 | Vertex Pharmaceuticals | 132.11 Bn | 124.26 Bn | 2.84 Bn | -153.00 |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | -571.00 |
| 5 | Argenx Se | 61.69 Bn | 56.50 Bn | 1.37 Bn | 553.00 |
| 6 | Moderna | 54.62 Bn | 49.48 Bn | 52.00 Mn | 4,709.00 |
| 7 | Alnylam Pharmaceuticals | 34.14 Bn | 30.84 Bn | 992.69 Mn | 1,911.00 |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | -2,328.00 |
| 9 | Roivant Sciences | 30.09 Bn | 30.09 Bn | 1.16 Mn | -801,907.00 |
| 10 | Insmed | 28.32 Bn | 27.16 Bn | 358.27 Mn | 29,565.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -801,907.00 |
| Dec 31, 2025 | -1.03 Mn |
| Sep 30, 2025 | -510,960.00 |
| Jun 30, 2025 | -1.22 Mn |
| Dec 31, 2024 | -2.40 Mn |
| Sep 30, 2024 | 160,334.00 |
| Jun 30, 2024 | 126,221.00 |
| Dec 31, 2023 | 2.48 Mn |
| Sep 30, 2023 | -411,405.00 |
| Jun 30, 2023 | 659,074.00 |
| Dec 31, 2022 | -171,143.00 |
| Sep 30, 2022 | -89,309.00 |
| Jun 30, 2022 | -679,319.00 |
| Dec 31, 2021 | 342,426.00 |
| Sep 30, 2021 | 237,960.00 |
| Jun 30, 2021 | -87,688.00 |